Sudarshan Pharma Unleashes ₹1,500 Cr Global Raise Across Equity and Bonds

Sudarshan Pharma Industries Ltd has approved an aggregate fund-raising plan valued up to ₹1,500 crore, indicating its intention to grow its operations and reach out further overseas. The proposal was approved by the board on June 19, 2025, allowing the company to raise funds from a mix of equity shares, foreign currency convertible bonds (FCCBs), American Depository Receipts (ADRs), Global Depository Receipts (GDRs), and debentures, in one or more tranches.

Key Points:

- Mobilisation of funds will be achieved through public or private issues, including qualified institutional placements (QIPs) and preferential allotments, with regulatory approvals.
- The move is aimed at strengthening the balance sheet, funding expansion, and funding international acquisitions.
- The company has just completed a 1:10 stock split, improving liquidity and retail investor involvement.
- Sudarshan Pharma's FY24 net sales stood at ₹463.5 crore with a focus on APIs, specialty chemicals, and contract manufacturing.
- The board previously sanctioned the acquisition of its Singaporean unit as it pursued its international ambitions.
- The company also issued 9 lakh convertible warrants worth more than ₹15 crore in December 2024, again evidencing strong promoter optimism.

Prognosis:

With this diversified multi-instrument capital raising strategy, Sudarshan Pharma is set to achieve rapid growth in Indian as well as global markets. Diversified capital raising is a true testament to its vision of spearheading the pharma and specialty chemicals sector.

Sources: Rediff MoneyWiz, Goodreturns, Sudarshan Pharma Investor Presentation